| Typicality: | 0.317 |
| Saliency: | 0.157 |
| in combination with atezolizumab | 6 | other |
| trial → assess → anti-tumor activity | 5 |
| trial → study → anti-tumor activity | 3 |
| negative | neutral | positive |
| 0.018 | 0.867 | 0.115 |
| Raw frequency | 8 |
| Normalized frequency | 0.157 |
| Modifier score | 0.500 |
| Perplexity | 58.487 |